[go: up one dir, main page]

AR130287A1 - Métodos para la fabricación de inhibidores de quinasa - Google Patents

Métodos para la fabricación de inhibidores de quinasa

Info

Publication number
AR130287A1
AR130287A1 ARP230102240A ARP230102240A AR130287A1 AR 130287 A1 AR130287 A1 AR 130287A1 AR P230102240 A ARP230102240 A AR P230102240A AR P230102240 A ARP230102240 A AR P230102240A AR 130287 A1 AR130287 A1 AR 130287A1
Authority
AR
Argentina
Prior art keywords
methods
manufacture
kinase inhibitors
disclosure provides
tnik
Prior art date
Application number
ARP230102240A
Other languages
English (en)
Inventor
Xing Liang
Hua Cao
Xin Cheng
Luoheng Qin
Original Assignee
Insilico Medicine Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insilico Medicine Ip Ltd filed Critical Insilico Medicine Ip Ltd
Publication of AR130287A1 publication Critical patent/AR130287A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En un aspecto, la descripción proporciona métodos para sintetizar inhibidores de quinasas TNIK y/o MAP4K4 para el tratamiento de la enfermedad. En un aspecto, la descripción proporciona compuestos intermedios usados en los métodos de síntesis descritos en la presente. Un método para producir un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable del mismo.
ARP230102240A 2022-08-24 2023-08-23 Métodos para la fabricación de inhibidores de quinasa AR130287A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022114447 2022-08-24

Publications (1)

Publication Number Publication Date
AR130287A1 true AR130287A1 (es) 2024-11-20

Family

ID=90012561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102240A AR130287A1 (es) 2022-08-24 2023-08-23 Métodos para la fabricación de inhibidores de quinasa

Country Status (9)

Country Link
EP (1) EP4577524A1 (es)
JP (1) JP2025527659A (es)
KR (1) KR20250051740A (es)
CN (1) CN119923387A (es)
AR (1) AR130287A1 (es)
AU (1) AU2023327885A1 (es)
CA (1) CA3265130A1 (es)
TW (1) TW202416964A (es)
WO (1) WO2024041555A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133181A1 (es) * 2023-07-06 2025-09-03 Insilico Medicine Ip Ltd Inhibidor cristalino del tnik y usos del mismo
AR133230A1 (es) * 2023-07-14 2025-09-10 Insilico Medicine Ip Ltd Formulaciones farmacéuticas para inhalación y usos de las mismas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
US11739078B2 (en) * 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
US20240336611A1 (en) * 2021-02-24 2024-10-10 Insilico Medicine Ip Limited Analogs for the treatment of disease
WO2022179528A1 (en) * 2021-02-24 2022-09-01 Insilico Medicine Ip Limited Analogs for the treatment of disease

Also Published As

Publication number Publication date
CA3265130A1 (en) 2024-02-29
KR20250051740A (ko) 2025-04-17
WO2024041555A1 (en) 2024-02-29
CN119923387A (zh) 2025-05-02
TW202416964A (zh) 2024-05-01
JP2025527659A (ja) 2025-08-22
AU2023327885A1 (en) 2025-03-06
EP4577524A1 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
AR130287A1 (es) Métodos para la fabricación de inhibidores de quinasa
CL2024002874A1 (es) Inhibidores de kras
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
CO2021016295A2 (es) Compuestos de pirrolidina
CL2021002244A1 (es) Compuesto inhibidor de jak y uso del mismo
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
CO2025013134A2 (es) Inhibidores de kras
AR126251A1 (es) Inhibidores de cdk2
MX2025011447A (es) Inhibidores de kras
EA202193015A1 (ru) Ингибиторы cdk
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
CL2023001367A1 (es) Inhibidores de btk
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
AR126849A1 (es) Compuestos de quinazolina para tratamiento de enfermedad
MX2025002218A (es) Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CL2025001258A1 (es) Proceso de elaboración de derivados de morfolinas sustituidas
CL2021003139A1 (es) Compuestos tricíclicos
UY39799A (es) Compuestos de pirrolil–sulfonamida
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.